CDK4 and lung carcinoma: miR-340 also inhibits lung cancer cell proliferation by targeting CDK4 40; while it has been reported that CDK4 is involved in accelerating NSCLC cancer procession and combined inhibition of CDK4 could be effective to treat NSCLC 45.